Jean Bergeron is a physician acting as consultant and clinical scientist at the, Endocrinology and Nephrology Research Unit, Centre de recherche du CHU de Québec – Université Laval, as well as Professor at the Molecular Biology, Medical Biochimistry and Pathology Department, Faculty of Medicine, Laval University. He is member of the Medical Biochimistry Unit (Department of Laboratory Medicine) and chief of the Lipid clinic (Department of Medicine) of the CHU de Québec-Université Laval. He is also Secretary for the Société Québécoise de Lipidologie, Nutrition et Métabolisme (SQLNM), a scientific society from which he received in 2012 a recognition award, Le prix des Fondateurs Jean Davignon et Paul-J. Lupien, for his outstanding contribution in the field of lipidology. As specialist in laboratory medicine and lipidology, he supervises the CHU de Québec – Laval University clinical lipid laboratory performing lipoprotein, lipid and gene analyses.

 

Interest in clinical research

During his career, he has been dedicated to a better understanding of clinical and biological expressions of primary and secondary hyperlipidemia. He has also participated in the development and application of up to date lipid guidelines for clinicians and contributed to the characterization of new metabolic markers related to atherosclerosis and heart disease. He participated to numerous clinical trials using statins and new emergent therapies in lipoprotein metabolism.

 

Actual clinical research

More recently, he is involved in research on statin-generated myopathy, including identification of blood or genetic markers related to statin side effect and development of clinical tools for a better support to patients suffering from this condition. He is involved in the Canadian Familial Hypercholesterolemia registry. Finally, he is principal investigator in several clinical trials using PCSK9 inhibitors, anti-sense oligonucleotides, ANGPTL-3 inhibitors, and in some cases, gene therapy for very severe hypercholesterolemia or patients at very high CV risk for premature atherosclerotic heart disease.

 

CHUL
2705, boulevard Laurier
C-00-224
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 42162
jean.bergeron@crchudequeb...

Latest news

Data not available

241 entries « ‹ 1 of 25 › »

Leiter LA, Hegele RA, Brown V, Bergeron J, Mackinnon ES, Mancini GBJ

Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease

Journal Article

Rev Cardiovasc Med, 25 (5), 2024.

Abstract | Links:

Murphy-Després A, Chartrand DJ, Lemieux I, Tremblay A, Bergeron J, Poirier P, Alméras N, Després JP

Long-Term Improvement in Cardiorespiratory Fitness Ameliorates Insulin Sensitivity beyond Changes in Visceral/Ectopic Fat among Men with Visceral Obesity

Journal Article

Nutrients, 16 (9), 2024.

Abstract | Links:

Al-Baldawi Z, Brown L, Ruel I, Baass A, Bergeron J, Cermakova L, Couture P, Gaudet D, Francis GA, Hegele RA, Iatan I, Mancini GBJ, McCrindle BW, Ransom T, Sherman MH, McPherson R, Genest J, Brunham LR

Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia

Journal Article

J Clin Lipidol, 18 (2), 2024.

Abstract | Links:

Peyrel P, Mauriège P, Frenette J, Laflamme N, Greffard K, Dufresne SS, Huth C, Bergeron J, Joanisse DR

No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized controlled trial

Journal Article

J Clin Lipidol, 18 (2), 2024.

Abstract | Links:

Santos RD, Ruzza A, Wang B, Maruff P, Schembri A, Bhatia AK, Mach F, Bergeron J, Gaudet I, St Pierre J, Kastelein JJP, Hovingh GK, Wiegman A, Gaudet D, Raal FJ

Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment

Journal Article

Eur J Prev Cardiol, 31 (3), 2024.

Abstract | Links:

Brown L, Ruel I, Baass A, Bergeron J, Brunham LR, Cermakova L, Couture P, Gaudet D, Francis GA, Hegele RA, Iatan I, Mancini GBJ, McCrindle BW, Ransom T, Sherman MH, McPherson R, Genest J

Design, Rationale, and Preliminary Results of the Canadian Homozygous Familial Hypercholesterolemia Registry: 2008 to 2022 Update

Journal Article

Canadian journal of health technologies, 3 (2), 2023.

| Links:

Rosenson RS, Gaudet D, Ballantyne CM, Baum SJ, Bergeron J, Kershaw EE, Moriarty PM, Rubba P, Whitcomb DC, Banerjee P, Gewitz A, Gonzaga-Jauregui C, McGinniss J, Ponda MP, Pordy R, Zhao J, Rader DJ

Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial

Journal Article

Nat Med, 29 (3), 2023.

Abstract | Links:

Peyrel P, Mauriège P, Frenette J, Laflamme N, Greffard K, Dufresne SS, Huth C, Bergeron J, Joanisse DR

Impact of statin withdrawal on perceived and objective muscle function

Journal Article

PLoS One, 18 (6), 2023.

Abstract | Links:

Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D, Stein E,

Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial

Journal Article

Eur Heart J, 44 (40), 2023.

Abstract | Links:

Gupta M, Wani RJ, Al Faraidy K, Bergeron J, Contreras E, Peña AAG, Mancini GBJ, Padilla F, Lopez AAP, Philip K, Wu J, Mackinnon ES

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study

Journal Article

Cardiol Ther, 12 (4), 2023.

Abstract | Links:

241 entries « ‹ 1 of 25 › »
Signaler des ajouts ou des modifications

Recently finished projects

  • Support clinico-administratif pour patients et médecins pour l'utilisation de nouveaux agents biologiques pour le traitement de l'hypercholestérolémie, from 2019-01-30 to 2024-03-31
Data provided by the Université Laval research projects registery